News Releases

Allons Data Safety Monitoring Board recommends continuation of pivotal clinical trial

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley will present an update of the Company’s progress on Tuesday, February 14th at the 14th Annual BIO CEO & Investor Conference in New York City. During that presentation, McCauley will also discuss the latest ... Continue reading →

Allon shareholders approve balance of October prospectus financing

VANCOUVER, B.C. — Allon Therapeutics Inc.(TSX: NPC), today announced that its shareholders have approved the investment by Neuro Discovery II Limited Partnership (“ND II LP”) which was made as part of its  October 2011 prospectus offering.  The prospectus offering resulted in gross proceeds of $5... Continue reading →

Allons intellectual property portfolio strengthened with additional U.S. patent

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that it has been granted a United States patent covering the use of Allon’s drug candidates, including its lead product davunetide, and other pipeline products, for the treatment of laser induced retinal damage.  This new patent... Continue reading →

Allon invited to present at two major conferences

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley has been invited to present an update of the Company’s business progress on Tuesday, November 29, 2011 at the Piper Jaffray Health Care Conference in New York City.  McCauley’s presentation will include an upda... Continue reading →

Allon Therapeutics releases Q3 operating results and provides corporate update

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) today announced its unaudited operating results for the three and nine month periods ended September 30, 2011. Allon also said that two events subsequent to the end of the Third Quarter have kept the Company on track to achieve its objective of... Continue reading →

← Older posts Newer posts →